Regeneron Pharmaceuticals, Inc. REGN
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) EV/Sales
As of 25 September 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 3.3× (June 2025) to 17.9× (June 2015); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 10.7× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.3× | 4.97% |
| FY2024 | 5.0× | (26.15%) |
| FY2023 | 6.8× | 13.57% |
| FY2022 | 6.0× | 50.84% |
| FY2021 | 4.0× | (35.91%) |
| FY2020 | 6.2× | 5.41% |
| FY2019 | 5.9× | (20.91%) |
| FY2018 | 7.4× | 9.08% |
| FY2017 | 6.8× | (15.33%) |
| FY2016 | 8.0× | (40.32%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.8× | (23.99%) |
| Mar 2026 | 5.0× | (5.46%) |
| Dec 2025 | 5.3× | 41.00% |
| Sep 2025 | 3.7× | 3.86% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | 4.9× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.0× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.6× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 10.0× |
| ARGX argenex SE compare | 10.5× |
| RPRX Royalty Pharma PLC compare | 13.4× |
| INSM Insmed, Inc. compare | 22.2× |
| MRNA Moderna, Inc. compare | 33.5× |
| RVMD Revolution Medicines, Inc. compare | 1,499× |
| Biotechnology industry median | 10.7× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement